BACKGROUND: There is a paucity of information about treatment and mortality trends after acute myocardial infarction (AMI) for cancer survivors (CS). METHODS: In this population-based study, the authors compared temporal trends of treatments and outcomes (mortality, nonfatal cardiovascular outcomes), among CS and patients without cancer (the noncancer patient [NCP] group) with AMI in Ontario (Canada) using inverse probability treatment weight (IPTW)-adjusted modeling. RESULTS: Of 270,089 patients with AMI (22,907 CS, 247,182 NCP, 1995; median follow-up, 10.1 and 11.0 years, respectively), the use of invasive coronary strategies and pharmacotherapies increased and mortality declined for CS and NCP (all P trend < .001). At 30 days after AMI, there was no difference between CS and NCP in the receipt of coronary angiography (incidence risk ratio [IRR], 0.98; 95% confidence interval [CI], 0.96-1.01; P 5.23), percutaneous coronary intervention (IRR, 0.98; 95% CI, 0.94-1.02; P 5.29), or bypass (IRR, 0.93; 95% CI, 0.85-1.02; P 5.11). At 90 days after AMI, there was no difference in the receipt of b-blockers, clopidogrel, or nitrates; but CS were less often prescribed angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers and statins. CS had higher all-cause mortality at 30 days (adjusted hazard ratio [HR] 1.12; 95% CI, 1.07-1.17; P <.001), at 1 year (1.16; 95% CI, 1.12-1.20; P <.001), and long term (HR, 1.21; 95% CI, 1.17-1.25; P <.001) and had a greater risk of heart failure (HR, 1.08; 95% CI, 1.03-1.14; P 5.001), but not myocardial re-infarction (HR, 0.98; 95% CI, 0.95-1.01; P 5.22) or stroke (HR, 1.06; 95% CI, 0.97-1.16; P 5.18). CONCLUSIONS: Among CS and NCP with AMI in Ontario, similar improvements in mortality and receipt of treatments were observed between 1995 and 2013. However, compared with NCP, CS had a higher risk of mortality and heart failure.
INTRODUCTION
Cardiovascular disease and cancer are leading causes of mortality worldwide. 1 Over the last 2 decades, deaths from cancer have declined because of earlier detection and modern treatment regimens. Many patients diagnosed with cancer will not die from it; often, their cancer is either cured or becomes a chronic disease when a cure cannot be achieved, leading to a growing population of cancer survivors. 2 Likewise, there has been a global decline in deaths from acute myocardial infarction (AMI) associated with an increase in the use of guideline-indicated prevention strategies and treatments. 3, 4 Data suggest that noncancer-related mortality from cardiovascular disease has become increasingly important during cancer survivorship. 5, 6 Many types of cancer have been associated with an increased risk of coronary artery disease (CAD). 7 Cancer and CAD have many shared risk factors, including tobacco use and a sedentary lifestyle [8] [9] [10] ; cancer is also associated with hypercoagulability and atherosclerosis 11 and with cardiovascular events, such as heart failure (HF) and ischemia. [12] [13] [14] The management of cardiovascular diseases among cancer survivors poses a unique challenge to clinicians. 15, 16 In part, this is because there is a paucity of detailed yet generalizable information regarding cardiovascular care and outcomes after AMI in cancer survivors versus patients without cancer. Certainly, preventative care and treatment of cardiovascular comorbidities is critically important to improve outcomes during survivorship in this vulnerable population. Multisource electronic health records provide an opportunity to perform high-resolution investigations of common diseases. Accordingly, providing insights into longer term outcomes for cancer survivors with AMI may highlight opportunities for enhanced delivery of cardiovascular care. The objective of the current study was to investigate whether the previously reported increase in the use of treatments for AMI (among patients without cancer) and the associated decline in mortality were evident among cancer survivors in Ontario (Canada) with AMI.
MATERIALS AND METHODS

Data Sources
Patient characteristics, chemotherapies, medications, and outcome information were obtained from the following Ontario databases: the Registered Persons Database for demographics and vital status; the Ontario Cancer Registry (OCR) for cancer diagnosis; the Canadian Institute of Health Information (CIHI)-Discharge Abstract Database for admission and discharge data; the Ontario Health Insurance Plan for cardiac risk factors and comorbidities; the Ontario Drug Benefits database for medication data on patients aged 65 years; the CIHI-National Ambulatory Care Reporting System for emergency department visits; and the New Drug Funding Program for adjuvant systemic therapy details. Detailed information is reported in Supporting Table 1 (see online supporting information).
Cohort Selection
Although there is no uniform definition for cancer survivors, 17 we aimed to identify a subset of patients who had cancer in clinical remission, 18, 19 because we wanted to address whether a diagnosis of cancer in the past could result in unjustifiable biases in cardiovascular care and to delineate any actionable care gaps. Accordingly, our main objective was to evaluate cardiovascular care and outcomes after an AMI that occurred during cancer survivorship in those with no apparent recurrent or metastatic disease (to isolate the effect of a past history of cancer diagnosis from active malignancy).
Cancer survivors who were unlikely to be in relapse were identified by the following criteria: 1) the index AMI occurred at least 1 year after the initial cancer diagnosis (cancer types are listed in Supporting Table 3 ; see online supporting information), 2) the patient survived beyond 1 year after the date of cancer diagnosis without a second primary cancer diagnosis, and 3) the patient did not receive chemotherapy or radiation therapy beyond 1 year after diagnosis (surrogate for disease relapse and/or progression). For cohort derivation, all patients aged 18 years who had an AMI during an index hospital admission between January 1995 and December 2013 in Ontario, Canada, were identified through the CIHI Discharge Abstract Database 20 and were stratified as a cancer survivor (solid or hematologic) or patient without cancer (noncancer patient) (Supporting Fig. 1 ; see online supporting information). International Classification of Diseases ninth edition (ICD-9) and ICD-10 diagnostic codes were used to ascertain patients who had an AMI (ICD-9 code 410; ICD-10 codes I20, I21, I22, and I25) (Supporting Table 2 ; see online supporting information). After an AMI, the patients' treatments received and clinical outcomes were tracked by linkage of their unique code to the 7 databases; and, upon provision of the data for analysis, patient information was de-identified.
The primary outcome was all-cause mortality at 30 days, at 1 year, and at final follow-up (December 2014). The secondary outcomes were: nonfatal cardiovascular hospital admission for HF (ascertained using a validated algorithm for identifying HF 21 ), myocardial re-infarction or stroke that occurred during overall follow-up and within 1-year of AMI; rates of using an invasive coronary strategy, including coronary angiography, percutaneous coronary intervention (PCI), and coronary artery bypass graft (CABG) surgery, within 30 days of AMI; cardiovascular pharmacotherapies prescribed within 90 days (only for patients aged 65 years, because no reliable medication data were available for patients aged <65 years). Subsequently, the temporal relation of these outcomes with time (from 1995 to 2013) were examined and compared between cancer survivors and patients without cancer.
Ethical Approval
Research Ethics Board approval was obtained from Sunnybrook Health Sciences Center (REB number 033-2013; approved April 2013).
Statistical Analysis
Unadjusted and adjusted baseline characteristics were described as percentages for all baseline categorical variables. Given the potential for confounding by indication, we used propensity score-derived inverse probability of treatment weights (IPTW)s to directly compare outcomes in cancer survivors and patients without cancer. First, propensity scores were calculated using logistic regression and comprised age, sex, rural residence, income, geographic location, hypertension, diabetes, dyslipidemia, anemia, Original Article gastrointestinal bleed, stroke, peripheral vascular disease, arrhythmias, Charlson comorbidity score, aggregated disease groups, baseline cardiovascular medications, and receipt of coronary angiography, PCI, or CABG surgery before the index AMI. Subsequently, IPTWs were computed as the reciprocal of the propensity score.
The time-to-first nonfatal cardiovascular outcomes and mortality were compared between cancer survivors and patients without cancer using IPTW-adjusted Cox proportional-hazard modeling. Patients who did not develop the corresponding endpoint by the end of the observation period (December 2014) were censored. Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ADG, aggregated disease groups; AMI, acute myocardial infarction; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass graft surgery; CCB, calcium channel blocker; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; HF, heart failure; HR, hazard ratio; IPTW, inverse probability treatment weight; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease.
Exploratory analyses were conducted to compare the risk of HF breast cancer survivors, many of whom likely received anthracycline-based chemotherapy with or without trastuzumab (well known to cause type 1 and type 2 cardiotoxicity, respectively 13 ), and nonbreast cancer survivors with the risk of HF in patients without cancer. The use of an invasive coronary strategy within 30 days and receipt of pharmacotherapies within 90 days after AMI were estimated using IPTW-adjusted, modified Poisson regression. 22 For temporal trends of IPTW-adjusted rates of cardiac care and outcomes after AMI between 1995 and 2013, Poisson regression was used to estimate the annual average percent change (AAPC) and P trend for both cancer survivors and the noncancer patient group. Ancillary analyses were conducted to delineate whether there was a significant interaction between cancer survivor status and time for each outcome using logistic regression to obtain P interaction .
To ascertain the influence of the length of time from cancer diagnosis to the index AMI, we conducted subgroup analysis in which patients with cancer were separated into those who had an AMI either within 1 to 5 years of cancer diagnosis or >5 years after cancer diagnosis. Adjusted comparisons of mortality and nonfatal cardiovascular outcomes were conducted as described above.
For all analysis, a 2-tailed P value < .05 was considered statistically significant. Statistical analysis was performed using SAS version 9.4 (SAS Institute, Inc., Cary, NC).
RESULTS
Patient Characteristics
We identified 270,089 patients who had an AMI, including 22 (Table 2) .
Temporal Trends in an Invasive Coronary Strategy
Between 1995 and 2013, the IPTW-adjusted use of an invasive coronary strategy within 30 days after AMI increased equally among cancer survivors and patients without cancer (P trend < .0001; P interaction 5 .93, .23, and .46 for coronary angiography, PCI, and CABG surgery, respectively) (Fig. 1A) . For cancer survivors and patients 
Cardiovascular Pharmacotherapies
At 90 days after the index AMI, the receipt of pharmacotherapies by cancer survivors versus patients without cancer (aged 65 years) was similar for b-blockers, calciumchannel blockers, clopidogrel, nitrates, and spironolactone (Table 2) . Conversely, cancer survivors were prescribed marginally less angiotensin-converting enzyme inhibitor (ACEi)/angiotensin II receptor blocker (ARB) (IRR, 0.98; 95% CI, 0.97-0.99, P 5 .0015), statins (IRR, 0.96; 95% CI, 0.95-0.98; P < .0001), and oral anticoagulants (IRR, 0.93; 95% CI, 0.89-0.97, P 5 .0003).
Temporal Trends in Cardiovascular Pharmacotherapies
Between 1995 and 2013, the IPTW-adjusted prescription of pharmacotherapies within 90 days of AMI increased similarly among cancer survivors and patients without cancer (all aged 65 years) for b-blockers and clopidogrel (all P trend < .001; P interaction 5 .82 and .15 for b-blockers and clopidogrel, respectively) (Fig. 1B) (AAPC, 2.3% [95% CI, 1.0%-3.6%] and 2.3% [95% CI, 1.0%-3.7%], respectively).
All-Cause Mortality
A cancer diagnosis before AMI was associated with higher 30-day mortality (hazard ratio [HR], 1.12; 95% CI, 1.07-1.17; P < .0001), 1-year mortality (HR, 1.16; 95% CI, 1.12-1.20; P < .0001) and worse overall survival (HR, 1.21; 95% CI, 1.17-1.25; P < .0001). At 1 year, the adjusted survival estimates were 76.8% for cancer survivors and 79.7% for patients without cancer (Fig. 2A) . The IPTW-adjusted 30-day, 1-year, and long-term all-cause mortality rates were 13.6%, 23.4%, and 54.8%, respectively, for cancer survivors and 12.3%, 20.4%, and 49.0%, respectively, for patients without cancer.
Cancer survivors who were diagnosed with cancer 5 years after an AMI had a significantly greater risk of 30-day mortality (HR, 1.13; 95% CI, 1.07-1.20; P < .0001) compared with those who were diagnosed within 1 to 5 years of an AMI (HR, 1.09; 95% CI, 1.00-1.18, P 5 .054) (Supporting Table 4 ; see online supporting information). For 1-year mortality and overall survival, an increased mortality risk was observed for cancer survivors irrespective of their time from cancer diagnosis to the index AMI (Supporting Table 4 ; see online supporting information).
Temporal Trends in Mortality
At the start and end of the study period, the IPTWadjusted 30-day mortality rates were similar between cancer survivors and patients without cancer (1995: 17.1% vs 16.2%, respectively; 2013: 7.9% vs 7.5%, respectively) (Fig. 1C) . In addition, the IPTW-adjusted 1-year mortality rates in 1995 and 2013 were similar between cancer survivors and patients without cancer (1995: 25.1% vs 24.8%, respectively; 2013: 13.9% vs 14.1%, respectively) (Fig. 1C) .
Between 
Nonfatal Cardiovascular Outcomes
Over the follow-up period, cancer survivors had a higher risk of HF compared with noncancer patient group (HR, 1.08; 95% CI, 1.03-1.14, P 5 .0011), but they did not have a higher risk of myocardial re-infarction or stroke (Table 3 ). The composite of HF/myocardial re-infarction/stroke did not differ significantly between the 2 groups (HR, 1.00; 95% CI, 0.97-1.04, P 5 .85) (Fig.  2B ). In addition, breast cancer survivors had a greater risk of HF (HR, 1.33; 95% CI, 1.11-1.58; P 5 .0016) Figure 2 . A survival curve of long-term, all-cause mortality and nonfatal cardiovascular events during the entire follow-up of a retrospectively identified population cohort of cancer survivors with acute myocardial infarction (AMI) between 1995 and 2013 is compared with a noncancer control group of patients who had AMI. (A) Inverse probability treatment weight-adjusted all-cause mortality is illustrated. (B) An inverse probability treatment weight-adjusted composite outcome of heart failure, stroke, or myocardial re-infarction is illustrated.
compared with nonbreast cancer survivors (HR, 1.07; 95% CI, 1.02-1.12; P 5 .014).
With regard to the trend in cardiovascular outcomes that occurred within 1 year of AMI, between 1995 and 2013, the adjusted rates for HF (cancer survivors: AAPC, 21.6%; 95% CI, 24.5%, 1.3%; P trend 5 .27; noncancer group: AAPC, 0.9%; 95% CI, 23.8%, 2.1%; P trend 5 .54; P interaction 5 .095) and stroke (cancer survivors: AAPC, 1.9%; 95% CI, 24.9%, 9.2%; P trend 5 .59; noncancer patients: AAPC, 2.5%; 95% CI, 24.5%, 10.4%; P trend 5 .51; P interaction 5 .67) were similar between cancer survivors and patients without cancer (Fig. 1D) . For myocardial re-infarction, there was an increase in rates from 1995 to 2002 for both groups that stabilized thereafter (cancer survivors: AAPC, 7.5%; 95% CI, 6.0%-9.1%; P trend < .0001; noncancer patients: AAPC, 7.8%; 95% CI, 6.3%-9.4%; P trend < .0001; P interaction 5 .055).
DISCUSSION
This population-based study of 270,089 patients who had AMI investigated trends in cardiac care and outcomes between 1995 and 2013 among a subset of patients who had cancer in clinical remission (defined as cancer survivors in this study) compared with patients who had no history of cancer. Over the 18-year study period, we observed an increase in the use of coronary procedures and cardiovascular medications and similar rates of decline in 30-day and 1-year mortality in both cancer survivors and patients without cancer. Although we did not identify major differences in the delivery of cardiovascular care between patients with and without cancer, compared with patients who did not have cancer, cancer survivors who had AMI had a significantly higher risk of mortality and HF, but not myocardial re-infarction or stroke. These results reveal that cancer survivors with AMI may have worse outcomes compared with patients without cancer and emphasize the need for clinical attention to this expanding population.
The rate of decline in mortality observed in this study is consistent with that reported in the United States and in some European countries. 23, 24 However, our study suggests that these improvements in outcomes follow the timeline of increases in the receipt of evidence-based therapies and align with the results from studies of AMI among patients without cancer. 25 We observed that the rates of using an invasive coronary strategy after AMI did not differ between cancer survivors and patients without cancer, suggesting that the former had similar access to cardiac procedures. This finding is noteworthy, because there have been inconsistent findings with respect to the impact of coronary procedures on outcomes in patients with cancer. Analysis of a multicenter registry suggested that patients who had a cancer diagnosis up to, but not longer than, 6 months before an AMI and received PCI had significantly worse 1-year mortality compared with patients without cancer who had an AMI. 26 Another study indicated that patients who were diagnosed with cancer up to 1 year before receipt of PCI did not experience worse long-term cardiovascular outcomes compared with those who did not have cancer. 27 We observed that cancer survivors aged 65 years received similar rates of post-AMI cardiovascular pharmacotherapies, except for marginally less rates of ACEi/ARB, oral anticoagulants, and statins. The precise reason for less prescription of these medications is difficult to discern from our data set given the lack of granular data. Cancer survivors in our cohort were older and more comorbid than the control group. We postulate that, among cancer survivors, the greater prevalence of gastrointestinal bleeding and anemia may have potentiated the bleeding risk associated with oral anticoagulation, whereas renal disease may have precluded the receipt of an ACEi/ARB.
In terms of outcomes, cancer survivors had significantly worse survival compared with the noncancer patient group. A diagnosis of cancer before an AMI had a 12% and 21% higher risk for 30-day and long-term allcause mortality, respectively. There are several possible reasons for this. The acute-phase reactants and inflammation induced by cancer in the form of chemokines, cytokines, and platelet activation may accelerate atherosclerosis. 28 Radiation therapy is a well established risk factor for coronary artery disease, the consequences of which may become clinically significant many years later. 29, 30 Certain cancer therapies, such as anthracyclines, antimetabolites, hormone therapies, and new targeted and biologic agents, can have adverse cardiac effects. We observed that cancer survivors had a higher risk of HF, but not stroke or myocardial re-infarction. This latent risk for HF may be because of the cardiotoxic effects of commonly used cancer regimens (including anthracyclines, kinase inhibitors, and trastuzumab 32 ), although we cannot exclude the possibility that there was excess myocardial damage at the index AMI in patients with cancer despite similar rates of treatment. Anthracyclines have been associated with acute, early, and late cardiac events because of type 1 cardiotoxicity. Similarly, although trastuzumab is known to cause reversible type 2 cardiotoxicity, long-term cardiovascular complications remain pertinent in survivorship. 33 Although HF was not a main endpoint in this study, in an exploratory analysis, we observed that the post-AMI risk of HF was greater in breast cancer survivors than in nonbreast cancer survivors. These results may be consistent with the notion that preexisting cardiac dysfunction may lead to worse outcomes post-AMI. Finally, cancer survivors tended to be anemic at baseline, possibly because of chemotherapy-induced bone marrow toxicity, nutritional deficiencies, and increased hepcidin, 34 which may have contributed to the risk of HF and ischemia. 35, 36 Cardiovascular prognosis among cancer survivors is complex and is traditionally categorized as phases of survivorship. 37 Because cardiovascular events that occur during the initial period immediately after cancer treatment may have different prognostic impact than events that occur late after a cancer diagnosis, 38, 39 we conducted subgroup analyses by cancer diagnosis from 1 to 4 years versus 5 years before AMI. We identified no difference in the risk of mortality with regard to the time from cancer diagnosis to AMI, highlighting the importance of diligent cardiovascular surveillance during sustained cancer survivorship.
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The current study has clinical implications. Although the continuing decline in mortality after AMI is encouraging, cardiovascular disease likely continues to be a leading cause of death among cancer survivors. 40 It is reassuring that a cancer diagnosis is not a deterrent to receiving invasive coronary strategy or pharmacotherapies after AMI. However, our results also highlight the importance of continued vigilance in cardiac risk surveillance during survivorship. It is crucial that cancer survivors continue to be evaluated for their risk of latent cardiovascular events, and future studies are needed to evaluate the effectiveness of such monitoring.
Although our current results are noteworthy, they are not without limitation. We could not attain the full array of covariates that may have an impact on outcomes, such as type of surgery, all chemotherapies, other treatments received, as well as granular details of radiation therapy. Therefore, we could not stratify our outcomes according to the type of treatment intervention received. The observational nature of this study also may result in unmeasured confounding that remained unaccounted for in IPTW. The cancer survivors in this study were a heterogeneous population with various cancer types and stages. Although this allowed for delineation of pre-existing malignancy as a risk factor for adverse outcomes overall, our study sample size lacked power to individually evaluate each cancer type. In addition, we may not have fully accounted for changes in cancer stage during follow-up because of inherent limitations of administrative databases. We tried to exclude cancer relapse by excluding patients who re-initiated systemic therapies during follow-up. We recognize that our study may have included patients with stage IV disease who had survived 1 year after diagnosis but did not receive additional therapy. There is also the possibility that a cancer survivor might be misclassified as a patient without cancer. The inability to capture events that occurred outside of Ontario might have resulted in under-reporting of outcomes. Our study precluded the opportunity to evaluate outcomes based on severity of myocardial damage, because we could not collect granular clinical data to accurately adjust for post-AMI prognosticators. Cause-specific mortality was also lacking in our data set; however, it is recognized that ascertainment of cause of death is likely inaccurate for several reasons and that all-cause mortality may be the most objective, unbiased endpoint. 41 Analyses of pharmacotherapies were limited to patients aged 65 years because of the lack of medication information in those aged <65 years (a recognized limitation of the Ontario administrative database). Ontario provides universal health care; hence, results herein may not be generalizable to other parts of the world where access to health care may be more limited. Moreover, characteristics of the cancer survivor population may vary regionally, and additional studies are required to confirm our results in other regions of the world. The objective of this observational study was to evaluate the association of cancer diagnosis with outcomes to provide insight into appropriate management strategies to enhance survivorship, rather than to establish causality per se.
In conclusion, our findings demonstrate that, over time, the use of coronary procedures increased and mortality decreased comparably in patients with AMI, irrespective of whether they had a previous cancer diagnosis. However, despite improvements in mortality trends, cancer survivors had excess numbers of short-term and longOriginal Article
